Analysis of cellular immune response in adults after administration of the coronavirus disease 2019 vaccine using the virus vector platform (Astra Zeneca)

Coronavirus Disease 2019 is caused by a novel virus that has never been identified or detected in humans before.To date, there is no specific treatment available for managing Covid-19 infection.To analyze the cellular immune response in adults 12 months after receiving the Covid-19 vaccine using the viral vector platform (AstraZeneca) as an alternative method to evaluate vaccination success.(AstraZeneca).The research sample consists of a group of recipients of the viral vector platform vaccine (AstraZeneca) for a period of 12 months since the second dose.Blood samples will be taken, followed by PBMC isolation and T cell immunophenotyping to calculate T cell and B cell subpopulations.Relevance of the research topic to the faculty's research roadmap: This study will explore the role of viral vector vaccination in the immune response to Covid-19.This objective is closely related to and supports the achievement of the 2016-2020 Strategic Plan and Master Plan for Research at Trisakti University, with a focus on biomedical and health behavior research.Preliminary results: The subjects involved in this study are mostly women, aged 36-45 years.They have received a third dose (booster) of the vaccine, have not been infected with Covid-19 in the past year, and show indications of prehypertension based on blood pressure measurements at the time of sampling.The patients' blood samples have undergone PBMC isolation and are currently stored.Immunophenotyping will be conducted to determine the T cell and B cell subpopulations using flow cytometry, which is currently in the optimization stage.Preliminary The subjects involved in this study are mostly women aged 36-45 years.They have received a third dose of the vaccine (booster), have not been infected with COVID-19 in the past year, and show indications of prehypertension based on blood pressure measurements taken at the time of sampling.Some of the samples that have undergone cellular immune response analysis show a percentage of CD4+ and CD8+ T cells of around 70%.